Klysmol (Sodium Phosphate Dibasic Heptahydrate, Sodium Dihydrogen Phosphate Monohydrate)

The active ingredients, sodium phosphate dibasic heptahydrate and sodium dihydrogen phosphate monohydrate, create an osmotic gradient in the colon. This gradient pulls water from surrounding tissues into the intestinal lumen, softening stool and stimulating peristalsis, which results in bowel movement.

The dose of Klysmol is determined by the prescribing healthcare professional based on the specific clinical situation, patient characteristics, and intended use. Patients should follow the prescriber’s instructions and not self‑adjust the amount.

Safety data for Klysmol in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To order Klysmol, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Klysmol is an osmotic laxative that uses phosphate salts to draw water into the colon, whereas other agents such as polyethylene glycol solutions rely on large volumes of fluid. Klysmol typically requires a smaller volume but may have a higher risk of electrolyte disturbances, so patient selection and monitoring differ.

Klysmol should be stored at room temperature, below 25 °C, in its original packaging. Keep it away from moisture and direct sunlight to maintain stability and potency.

Klysmol is supplied as a rectal solution and is administered via rectal insertion. The exact method, volume, and timing are determined by the prescribing clinician and should be performed under medical supervision.

Serious risks include severe electrolyte imbalances such as hyperphosphatemia, hypocalcemia, or hyperkalemia, acute renal dysfunction, marked dehydration, and, rarely, colonic perforation. Patients should be monitored closely for these complications, especially if they have pre‑existing kidney disease or are taking interacting medications.

Klysmol should not be used in patients with severe renal impairment, known bowel obstruction, or hypersensitivity to phosphate preparations. It is also contraindicated in individuals with uncontrolled electrolyte disorders or those at high risk for dehydration without appropriate medical oversight.